52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
about
52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
52-week results of the phase 3 ...... h active rheumatoid arthritis.
@en
52-week results of the phase 3 ...... h active rheumatoid arthritis.
@en-gb
52-week results of the phase 3 ...... h active rheumatoid arthritis.
@nl
type
label
52-week results of the phase 3 ...... h active rheumatoid arthritis.
@en
52-week results of the phase 3 ...... h active rheumatoid arthritis.
@en-gb
52-week results of the phase 3 ...... h active rheumatoid arthritis.
@nl
prefLabel
52-week results of the phase 3 ...... h active rheumatoid arthritis.
@en
52-week results of the phase 3 ...... h active rheumatoid arthritis.
@en-gb
52-week results of the phase 3 ...... h active rheumatoid arthritis.
@nl
P2093
P2860
P356
P1154
2-s2.0-85039847709
P1433
P1476
52-week results of the phase 3 ...... h active rheumatoid arthritis.
@en
P2093
Aaron Alejandro Barrera Rodriguez
Anna Sylwestrzak
Asta Baranauskaite
Barbara Stasiuk
Jeehoon Ghil
Jirí Vencovský
Piotr Leszczynski
Roma Milasiene
Soo Yeon Cheong
Vira Tseluyko
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEX269
P50
P5530
P577
2017-12-01T00:00:00Z
P6179
1090638785